{"text_format":"1","workbook":"xlsx","n_sheets":2,"sheets":["Extensions","Populationsudvidelser"],"not_rendered":{"charts":0,"images":1,"macros":1,"external_links":0,"defined_names":3,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Extensions","index":0,"n_rows":40,"n_cols":10,"rows_kept":40,"cut":false,"hidden":false,"merged":[[31,9,32,9],[33,9,34,9]]}
["Ansøgninger om Extensions* i godkendelsesproces hos EMA"]
[]
["Lægemiddelstof","Produktnavn","Virksomhed","ATC-kode","Procedurenr.","Extension type","Dispenseringsform; Styrke; Administrationsvej","Est. EU godkendelse","Summary of Opinion","Nuværende registreret dispenseringsform (Kilde: pro.medicin.dk)"]
["Ivacaftor","Kalydeco","Vertex Pharmaceuticals (Ireland) Limited","R07AX02 ","EMEA/H/C/002494/X/0083/G","Ny styrke","Film-coated tablets; 75 mg","2020-12-25",null,"Tabletter; 150 mg ivacaftor\nGranulat i brev; 25 mg, 50 mg eller 75 mg ivacaftor"]
["Iron","Velphoro","Vifor Pharma","V03AE05","EMEA/H/C/002705/X/0020/G","Ny dispenseringsform+styrke","Powder for oral suspension; 125mg","2020-12-25",null,"Tyggetablett; 500 mg"]
["Tezacaftor / ivacaftor","Symkevi","Vertex Pharmaceuticals (Ireland) Limited","R07AX31 ","EMEA/H/C/004682/X/0015/G","Ny styrke","Film-coated tablets; 50/75mg","2020-12-25",null,"Tabletter; 100 mg tezacaftor/150 mg ivacaftor"]
["Albutrepenonacog alfa","IDELVION","CSL Behring GmbH","B02BD04","EMEA/H/C/003955/X/0035","Ny styrke","Powder and solvent for solution for injection; 3500 IU (700 IU/ml)","2021-02-28",null,"Pulver og solvens til injektionsvæske; 250 IE, 500 IE, 1.000 IE eller 2.000 IE "]
["Dulaglutide","Trulicity","Eli Lilly Nederland B.V.","A10BJ05 ","EMEA/H/C/002825/X/0045","Ny styrke","Solution for injection; 3 mg and 4.5 mg","2020-11-01",null,"Injektionsvæske i fyldt pen; 0,75 mg eller 1,5 mg "]
["Dabigatran etexilate","Pradaxa","Boehringer Ingelheim International GmbH","B01AE07","EMEA/H/C/000829/X/0122/G","Ny dispenseringsform","Coated granules; 20 mg, 30 mg, 40 mg, 50 mg, 110 mg, 150 mg","2020-11-28",null,"Kapsler; 75 mg, 110 mg eller 150 mg "]
["Dabigatran etexilate","Pradaxa","Boehringer Ingelheim International GmbH","B01AE07","EMEA/H/C/000829/X/0122/G","Ny dispenseringsform","Powder and solvent for oral solution; 6.25 mg/ml","2020-11-28",null,"Kapsler; 75 mg, 110 mg eller 150 mg "]
["Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium","Trimbow","Chiesi Farmaceutici S.p.A.","R03AL09 ","EMEA/H/C/004257/X/0008/G","Ny styrke","172 μg / 5 μg / 9 μg","2021-01-23",null,"Inhalationsspray; 87 mikrogram/ 5 mikrogram/9 mikrogram"]
["Dolutegravir","Tivicay","ViiV Healthcare","J05AX12","EMEA/H/C/002753/X/0058/G","Ny dispenseringsform+styrke","Dispersible tablet; 5 mg","2021-02-17",null,"Tabletter; 10 mg, 25 mg eller 50 mg "]
["Botulinum toxin type a","Nuceiva","Evolus Pharma Limited","M03AX01","EMEA/H/C/004587/X/0005","Ny styrke","Powder for solution for injection in vial (glass); 50 U","2021-02-17",null,"Pulver til injektionsvæske; 100 E"]
["Thiotepa","Tepadina","ADIENNE S.r.l.","L01AC01 ","EMEA/H/C/001046/X/0036","Ny dispenseringsform+styrke","Powder and solvent for solution for infusion; 400mg","2020-12-26",null,"Pulver til koncentrat til infusionsvæske; 15 mg eller 100 mg "]
["Rivaroxaban","Xarelto","Bayer","B01AF01","EMEA/H/C/000944/X/0074/G","Ny dispenseringsform+styrke","Granules for oral suspension; 1mg/ml","2021-01-30",null,"Filmovertrukken tablett; 2,5 mg, 10 mg, 15 mg eller 20 mg"]
["Bedaquiline","Sirturo","Janssen-Cilag International NV","J04AK05","EMEA/H/C/002614/X/0036/G","Ny styrke","Tablet; 20 mg","2021-01-30",null,"Tabletter; 100 mg "]
["Ravulizumab","Ultomiris","Alexion","L04AA23","EMEA/H/C/004954/X/0004/G","Ny styrke","Concentrate for solution for infusion; 1100 mg","2021-01-30",null,"Koncentrat til infusionsvæske; 300 mg"]
["Secukinumab","Cosentyx","Novartis Europharm Limited","L04AC10","EMEA/H/C/003729/X/0059","Ny styrke","Solution for injection (in pre-filled syringe and pre-filled pen); 300 mg","2021-02-28",null,"Injektionsvæske i fyldt pen; 150 mg"]
["Stiripentol","Diacomit","Biocodex","N03AX17","EMEA/H/C/000664/X/0032","Ny styrke","Capsules; 100 mg","2021-03-25",null,"Hårde kapsler; 250 mg eller 500 mg\t\nPulver til oral suspension; 250 mg eller 500 mg\t"]
["Peginterferon beta-1a","Plegridy","Biogen Netherlands B.V.","L03AB13","EMEA/H/C/002827/X/0056","Ny administrationsvej","Intramuscular use","2021-03-25",null,"Injektionsvæske, opl. i pen; 63 mikrogram, 94 mikrogram eller 125 mikrogram\nInjektionsvæske, opl. i sprøjte; 63 mikrogram, 94 mikrogram eller 125 mikrogram"]
["Fluticasone furoate / umeclidinium / vilanterol","Trelegy Ellipta","GlaxoSmithKline","R03AL08","EMEA/H/C/004363/X/0012/G","Ny styrke","(Inhalation); 184mcg/55mcg/22mcg","2021-03-25",null,"Inhalationspulver; 92 + 55 + 22 mikrogram"]
["Fluticasone furoate / umeclidinium / vilanterol","Elebrato Ellipta","GlaxoSmithKline","R03AL08","EMEA/H/C/004781/X/0014/G","Ny styrke","(Inhalation); 184mcg/55mcg/22mcg","2021-03-25",null,"Ikke markedsført i Danmark. "]
["Fluticasone furoate / umeclidinium / vilanterol","Temybric Ellipta","GlaxoSmithKline","R03AL08","EMEA/H/C/005254/X/0004/G","Ny styrke","(Inhalation); 184mcg/55mcg/22mcg","2021-03-25",null,"Ikke markedsført i Danmark. "]
["Natalizumab","Tysabri","Biogen Netherlands B.V.","L04AA23","EMEA/H/C/000603/X/0116","Ny administrationsvej + dispenseringsform + styrke","Solution for injection; subcutaneous injection; 150 mg","2021-04-23",null,"Konc. til infusionsvæske, opl.; 300 mg"]
["Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium","Trimbow","Chiesi Farmaceutici S.p.A.","R03AL09 ","EMEA/H/C/004257/X/0012","Ny dispenseringsform + styrke","Inhalation powder; 88µg / 5µg / 9µg","2021-04-23",null,"Inhalationsspray, opløsning; 87 + 5 + 9 mikrogram"]
["Glecaprevir / pibrentasvir","Maviret","AbbVie Deutschland GmbH & Co. KG","J05AP57","EMEA/H/C/004430/X/0033/G","Ny dispenseringsform + styrke","Coated granules in sachet; 50/20 mg","2021-04-26",null,"Filmovertrukne tabletter; 100 + 40 mg"]
["Sodium phenylbutyrate","Pheburane","Eurocept International B.V","(A16AX03)","EMEA/H/C/002500/X/0026","Ny dispenseringsform + styrke","Oral solution; 350 mg/ml","2021-08-23",null,"Granulat; 1 g indeholder 483 mg natriumphenylbutyrat"]
["Sodium phenylbutyrate","Pheburane","Eurocept International B.V.","(A16AX03)","EMEA/H/C/002500/X/0028","Ny dispenseringsform + styrke","Film-coated tablets; 500 mg","2021-08-23",null,"Granulat; 1 g indeholder 483 mg natriumphenylbutyrat"]
[]
["*Extensions: Ny styrke, ny dispenseringsform eller ny administrationsvej for et allerede registreret lægemiddel. ",null,null,null,null,null,null,null,null,"Baseret på tilgængelig EMA-data d. 31-08-2020"]
[]
[null,null,null,null,null,null,null,null,null,"Horizon Scanning"]
[]
[null,null,null,null,null,null,null,null,null,"Vi hører meget gerne fra dig, hvis du har spørgsmål til listen."]
[]
[]
[null,null,null,null,null,null,null,null,null,"Mail: horizonscanning@amgros.dk"]
[null,null,null,null,null,null,null,null,null,"Amgros tlf.: 88 71 30 00"]
[]
[null,null,null,null,null,null,null,null,null,"Udarbejdet af: Anna Bergkvist Christensen d. 10-09-2020"]

{"sheet":"Populationsudvidelser","index":1,"n_rows":36,"n_cols":9,"rows_kept":36,"cut":false,"hidden":false,"merged":[[27,7,28,8],[29,7,30,8],[32,7,32,8],[33,7,33,8]]}
["Ansøgninger om populationsudvidelser* i godkendelsesproces hos EMA"]
[]
["Lægemiddelstof","Produktnavn","Virksomhed","ATC-kode","EMA procedurenummer","Kort indikation","Supplerende information","Est. EU godkendelse","Summary of Opinion"]
["Burosumab","CRYSVITA","Kyowa Kirin Limited","M05BX05","EMEA/H/C/004275/II/0010/G","Adults with X-linked hypophosphataemia (XLH)","Adults","2020-09-01","Summary of Opinion"]
["Darunavir","Prezista","Janssen-Cilag International NV","J05AE10","EMEA/H/C/000707/II/0107","HIV-1 infection","Aged 12 years and older with body weight at least 40 kg","2020-09-01","Summary of Opinion"]
["Lurasidone","Latuda","Sunovion Pharmaceuticals Europe Ltd ","N05AE05","EMEA/H/C/002713/II/0029","Schizophrenia","Adolescent from 13 to less than 18 years","2020-09-01","Summary of Opinion"]
["Sodium oxybate","Xyrem","UCB Pharma S.A.","N07XX04","EMEA/H/C/000593/II/0076","Extension of indication to include adolescents and children older then 7 years for Xyrem","Adolescents and children older than 7 years","2020-12-27"]
["Perampanel","Fycompa","Eisai GmbH","N03AX22","EMEA/H/C/002434/II/0047","Partial-Onset (focal) Seizures with or without secondary generalisation and Primary Generalised Tonic-Clonic Seizures with idiopathic generalised epilepsy","Paediatric patients from 2 to 11 years of age","2020-12-28"]
["Ceftazidime / avibactam","Zavicefta","AstraZeneca AB","J01DD52 ","EMEA/H/C/004027/II/0015","Treatment of cIAI and cUTI","Paediatric patients aged 3 months to less than 18 years","2020-12-26"]
["Delamanid","Deltyba","Otsuka Novel Products GmbH","J04AK06 ","EMEA/H/C/002552/II/0040","(Tuberculosis) ","Adolescents and children above 6 years with a body weight of at least 30 kg","2020-12-30"]
["Everolimus","Votubia","Novartis Europharm Limited","L01XE10","EMEA/H/C/002311/II/0061","Partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex, TSC","Patients from 6 months to less than 2 years of age.","2020-12-30"]
["Iron","Velphoro","Vifor Pharma","V03AE05","EMEA/H/C/002705/X/0020/G","CKD","Paediatric patients 2 years of age and older","2020-12-25"]
["Ivacaftor","Kalydeco","Vertex Pharmaceuticals (Ireland) Limited","R07AX02 ","EMEA/H/C/002494/X/0083/G","Cystisk fibros","Children aged 6 to less than 11 years","2020-12-25"]
["Tezacaftor / ivacaftor","Symkevi","Vertex Pharmaceuticals (Ireland) Limited","R07AX31 ","EMEA/H/C/004682/X/0015/G","(Cystic fibrosis)","Children aged 6 to less than 11 years old","2020-12-25"]
["Dabigatran etexilate","Pradaxa","Boehringer Ingelheim International GmbH","B01AE07","EMEA/H/C/000829/X/0122/G","(Anticoagulant)","Pediatric","2020-11-28"]
["Dolutegravir","Tivicay","ViiV Healthcare","J05AX12","EMEA/H/C/002753/X/0058/G","HIV","Children from 4 weeks of life and weighing at least 3 kilograms.","2020-11-17"]
["Bedaquiline","SIRTURO","Janssen-Cilag International NV","J04AK05","EMEA/H/C/002614/X/0036/G","(Tuberculosis)","Paediatric patients aged from 5 years to less than 18 years of age and weighing more than 15 kg","2020-12-30"]
["Dupilumab","Dupixent","Sanofi-aventis groupe","D11AH05","EMEA/H/C/004390/II/0027","Atopic dermatitis ","Patients from 6 years to 11 years","2020-12-30"]
["Rivaroxaban","Xarelto","Bayer","B01AF01","EMEA/H/C/000944/X/0074/G","Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence","Neonates, infants and toddlers, children, and adolescents aged less than 18 years","2020-12-30"]
["Glecaprevir / pibrentasvir","Maviret","AbbVie Deutschland GmbH & Co. KG","J05AP57","EMEA/H/C/004430/X/0033/G","Chronic hepatitis C infection","Children from 3 to 12 years of age","2020-12-26"]
["Adalimumab","Humira","Abbvie","L04AB04","EMEA/H/C/000481/II/0198","Moderately to severely active ulcerative colitis in paediatric patients","Paediatric patients","2020-11-30"]
["Ivacaftor","Kalydeco","Vertex Pharmaceuticals ","R07AX02","EMEA/H/C/002494/II/0086","Cystic fibrosis, with one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. \r\n","Infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg.","2020-11-30"]
["Pembrolizumab","Keytruda","Merck Sharp & Dohme B.V","L01XC18","EMEA/H/C/003820/II/0090","Monotherapy, RR classical Hodgkin lymphoma (cHL) who have failed ASCT following at least one prior therapy when ASCT is not a treatment option.","Adults and paediatric patients aged 3 years and older ","2021-01-25"]
["Lipegfilgrastim ","Lonquex","Teva B.V.","L03AA14","EMEA/H/C/002556/II/0058/G","(Neutropenia)","Paediatric population","2021-03-17"]
[]
["*Populationsudvidelse: En ny patientgruppe føjes til indikationen. Eksempel: Daptomycin til pædiatriske patienter mellem 1 og 17 år",null,null,null,null,null,null,null,"Baseret på tilgængelig EMA-data d. 31-08-2020"]
[]
[null,null,null,null,null,null,null,"Horizon Scanning"]
[]
[null,null,null,null,null,null,null,"Vi hører meget gerne fra dig, hvis du har spørgsmål til listen."]
[]
[]
[null,null,null,null,null,null,null,"Mail: horizonscanning@amgros.dk"]
[null,null,null,null,null,null,null,"Amgros tlf.: 88 71 30 00"]
[]
[null,null,null,null,null,null,null,null,"Udarbejdet af: Anna Bergkvist Christensen d. 10-09-2020"]